A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sunovion
ClinicalTrials.gov Identifier:
NCT00809757
First received: December 15, 2008
Last updated: July 1, 2013
Last verified: July 2013

December 15, 2008
July 1, 2013
December 2008
June 2013   (final data collection date for primary outcome measure)
Change from baseline to Visit 4 in the mean daily composite score based on the Pediatric Asthma Caregiver Assessments [ Time Frame: Days 0,14,28 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00809757 on ClinicalTrials.gov Archive Site
  • Changes from baseline to Visits 3 and 4 in the mean daily composite score based on the daytime and nighttime asthma symptom scores [ Time Frame: Days 0,14,28 ] [ Designated as safety issue: No ]
  • Change and percent change in the in-clinic PEF value from study baseline (Visit 2 predose) to postdose timepoints at Visit 2,3,4 timepoints in those subjects aged 24 to <48 months able to perform acceptable and reproducible PEF man [ Time Frame: Days 0,14,28 ] [ Designated as safety issue: No ]
  • Change and percent change in the at-home mean daily PEF value from study baseline (mean of the daily PEF values from Visit 1 and 2) to Visits 3 and 4 (mean of the daily PEF values in the week prior to the visit) in subjects aged 24 to <48 month [ Time Frame: Days -7, 0, 14, 28 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma
A Safety, Efficacy, and Tolerability Study of Daily Dosing With Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to <48 Months With Asthma

A Safety, Efficacy, and Tolerability Study of Daily Dosing with Levalbuterol Tartrate HFA MDI and Placebo in Subjects Aged Birth to <48 Months with Asthma.

This is a modified-blind, randomized, placebo-controlled, multicenter, parallel-group trial of levalbuterol HFA MDI administered using a facemask and holding chamber in subjects birth to <48 months with asthma. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Asthma
  • Drug: Levalbuterol
    90 ug Levalbuterol (2 actuations)
    Other Name: Xopenex HFA Inhalation Aerosol
  • Drug: Levalbuterol UDV TID
    0.31 ug Levalbuterol UDV TID
    Other Name: Xopenex Inhalation Solution
  • Drug: Placebo
    Placebo (2 actuations)
    Other Name: Placebo
  • Experimental: 1
    90 ug Levalbuterol (2 actuations)
    Intervention: Drug: Levalbuterol
  • Active Comparator: 2
    0.31 ug Levalbuterol UDV TID
    Intervention: Drug: Levalbuterol UDV TID
  • Placebo Comparator: 3
    Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
198
June 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject's parent/legal guardian must give written informed consent, including privacy authorization, prior to study participation. Complete documentation regarding the consent process must be recorded in the case report form (CRF) and source documentation.
  • Subject's parent/legal guardian must be willing and able to comply with the study procedures and visit schedules.
  • Subject, male or female, must be between the ages of birth and <48 months, exclusive, at the time of consent.
  • Subjects 24 to <48 months of age must have a history of physician-diagnosed asthma (defined as at least 3 episodes of respiratory symptoms consistent with asthma symptoms including, but not limited to, cough, wheeze, or dyspnea).
  • Subjects 0 to <24 months of age must have a history of 3 episodes of respiratory symptoms that in the judgement of the investigator could be consistent with asthma or reactive airways disease.
  • Subject must be in good health and not affected by any other chronic conditions, including respiratory disorders other than asthma.
  • In subjects with a chest radiograph (taken 12 months prior to screening visit), no evidence of any chronic cardiopulmonary condition other than asthma should be present as discerned by the Investigator.
  • Subject's parent/legal guardian must be able to complete the diary cards and medical event calendars (MEC) reliably on a daily basis and understand dosing instructions and questionnaire completion.

Exclusion Criteria:

  • Subject who requires or is expected to require any disallowed medications
  • Subject who has participated in an investigational drug study within 30 days prior to screening, or who is currently participating in another clinical trial.
  • Subject or parent/legal guardian who has daily commitments during the study that would interfere with trial measurements, compliance, or both.
  • Subject who has a history of hospitalization for asthma, reactive airways disease, or bronchospasm within 4 weeks prior to screening or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial.
  • Subject who has experienced significant blood loss within 60 days of study drug.
  • Subject with a clinical diagnosis of cystic fibrosis.
  • Subject who was born prematurely, defined as less than 38 weeks gestational age at birth, and is <1 year of age at screening
  • Subject whose body weight is less than 7.0 kg at screening. This minimum weight requirement is based upon standard pediatric growth charts [CDC 2000].
  • Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.
  • Subject using any prescription drug with which levalbuterol or racemic albuterol sulfate administration is contraindicated.
  • Subject with a history of life-threatening asthma, defined as previous asthma episodes requiring intubation or associated with hypercapnia, respiratory arrest, or hypoxic seizures.
  • Subject with clinically significant abnormalities that may interfere with the metabolism or excretion of the study drugs or study participation (eg, abnormalities of renal, hepatic, metabolic, or endocrine function).
  • Subject with a history of cancer.
  • Subject with any chronic or congenital cardiorespiratory condition other than asthma including, but not limited to, bronchopulmonary dysplasia, congenital heart disease, and cystic fibrosis.
  • Subject affected by an upper or lower respiratory tract infection in the 3 weeks prior to screening.
  • Subject with a history of ventilation for a respiratory condition occurring at or near birth, including those associated with prematurity or bronchopulmonary dysplasia. Ventilatory support for elective non-cardiopulmonary surgery is not exclusionary. - Subject with any clinically significant abnormal laboratory values (hematology, blood chemistry).
  • Subject with a clinically significant abnormal 12-lead ECG that would put the subject at risk for experiencing adverse cardiac effects.
  • Subject who is a relative of a staff member.
Both
up to 48 Months
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00809757
051-359
No
Sunovion
Sunovion
Not Provided
Study Director: Respiratory Medical Director, MD Sunovion Pharmaceuticals, Inc.
Sunovion
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP